InsightRX Reports Record Growth In Platform Adoption By Health Systems And Biopharma Companies
Precision dosing intelligence company tripled client base, expanded oncology focus, and developed new drug models in 2021.
“In a year marked by uncertainties from COVID, we’re fortunate to have surpassed our growth expectations by continuing to support health systems and biopharma companies in optimizing the safety and efficacy of medications,” said Sirj Goswami, PhD, CEO and co-founder of InsightRX. “We are proud to collaborate with so many innovative health systems and biopharma companies in order to improve clinical outcomes for patients receiving complex medical treatments.”
Since its founding in 2015, the company has realized steady growth in the number of pharmacology models—which describe a drug’s pharmacological effect for an individual patient over time—supported by its precision dosing platform. InsightRX Nova offers more than 80 PK/PD models, including 12 proprietary models resulting from its patented continuous learning process. More than 100 new PK/PD models are currently in development.